D Espinouse
Overview
Explore the profile of D Espinouse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sebban C, Lefranc A, Perrier L, Moreau P, Espinouse D, Schmidt A, et al.
Eur J Cancer
. 2012 Jan;
48(5):713-20.
PMID: 22248711
Aim: To evaluate in a multicentre randomised study the effect on duration of febrile neutropenia (FN), the safety and cost-effectiveness of a single subcutaneous pegfilgrastim injection compared with daily injections...
2.
Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C, et al.
Ann Oncol
. 2007 Dec;
19(4):774-9.
PMID: 18065404
Background: Non-Hodgkin's lymphoma (NHL) in patients older than 80 years is not a rare disease and treatment strategies are often difficult because of associated comorbidities. Patients And Methods: We entered...
3.
Cayuela J, Rousselot P, Nicolini F, Espinouse D, Ollagnier C, Bui-Thi M, et al.
Leukemia
. 2005 Oct;
19(12):2334-6.
PMID: 16224485
No abstract available.
4.
Hequet O, Le Q, Moullet I, Pauli E, Salles G, Espinouse D, et al.
J Clin Oncol
. 2004 May;
22(10):1864-71.
PMID: 15143078
Purpose: To assess the cardiac status of the long-term survivors and to estimate the incidence and the features of subclinical cardiotoxicity induced after conventional treatment with doxorubicin for non-Hodgkin's lymphoma...
5.
Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F, et al.
Bone Marrow Transplant
. 2004 Mar;
33(9):921-3.
PMID: 15034544
Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present...
6.
Hequet O, Salles G, Ketterer N, Espinouse D, Dumontet C, Thieblemont C, et al.
Bone Marrow Transplant
. 2003 Jun;
32(1):89-95.
PMID: 12815483
The pathogenesis of thrombocytopenia occurring after autologous stem cell transplantation (ASCT) remains unclear. Six cases of classical peripheral thrombocytopenia that developed after ASCT for non-Hodgkin's lymphoma (NHL) are presented. Resolution...
7.
Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P, et al.
Bone Marrow Transplant
. 2002 Nov;
30(11):769-75.
PMID: 12439700
High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hematological side-effect....
8.
Hequet O, Dumontet C, Salles G, Espinouse D, Arnaud P, Thieblemont C, et al.
Bone Marrow Transplant
. 2002 Apr;
29(6):544.
PMID: 11960281
No abstract available.
9.
Seve P, Thieblemont C, Dumontet C, Bouafia F, Arnaud P, Hequet O, et al.
J Clin Oncol
. 2001 Apr;
19(7):2100-1.
PMID: 11283146
No abstract available.
10.
Dumontet C, Thieblemont C, Espinouse D, Bouafia F, Hequet O, Salles G, et al.
Leukemia
. 2001 Feb;
14(12):2159-65.
PMID: 11187906
Patients with NHL and two or three factors of the International Prognostic Index (IPI) have a poor prognosis. We performed a prospective trial of intensive induction therapy followed with high-dose...